REGN
Regeneron Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$672.15-0.67%
Price as of Jul 20, 2026
REGN financials
Regeneron Pharmaceuticals, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $14.3B | $14.2B | $13.1B | $12.2B |
| Cost of revenue | $2.1B | $2.0B | $2.2B | $1.7B |
| Gross profit | $12.2B | $12.2B | $10.9B | $10.5B |
| Operating expenses | $8.7B | $8.2B | $6.5B | $5.1B |
| Operating income | $3.6B | $4.0B | $4.3B | $5.4B |
| Net income | $4.5B | $4.4B | $4.0B | $4.3B |
| EBITDA | $5.8B | $5.3B | $4.7B | $5.3B |
| Basic EPS | $43.07 | $40.90 | $37.05 | $40.51 |
| Diluted EPS | $41.48 | $38.34 | $34.77 | $38.22 |
| Balance sheet | ||||
| Cash & equivalents | $3.1B | $2.5B | $2.7B | $3.1B |
| Total assets | $40.6B | $37.8B | $33.1B | $29.2B |
| Total liabilities | $9.3B | $8.4B | $7.1B | $6.6B |
| Stockholders’ equity | $31.3B | $29.4B | $26.0B | $22.7B |
| Total debt | $2.7B | $2.7B | $2.7B | $2.7B |
| Net debt | -$412.2M | $216.2M | -$27.1M | -$404.5M |
| Cash flow | ||||
| Operating cash flow | $5.0B | $4.4B | $4.6B | $5.0B |
| Capital expenditure | -$898.4M | -$755.9M | -$926.4M | -$590.1M |
| Free cash flow | $4.1B | $3.7B | $3.7B | $4.4B |
| Dividends paid | -$370.3M | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$4.0B | -$3.6B | -$2.2B | -$2.5B |